On March 15, 2022 Mission Therapeutics ("Mission"), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), reported that Dr Paul Thompson, the Company’s Chief Scientific Officer, will present at the 2nd Annual Target Protein Degradation (TPD) Europe Summit in London (15-17 March) (Press release, Mission Therapeutics, MAR 15, 2022, View Source [SID1234610090]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At 9.00 AM GMT on 17 March, Dr Thompson will present on Mission’s "Novel DUB Inhibitor Platform Addressing Protein Homeostasis". Currently Mission’s CSO, Dr Thompson joined Mission in 2016. He has over 15 years of experience in translational research and early clinical development.

The annual TPD Europe Summit provides a platform of learning, discovery, and networking opportunities, to hear about the latest developments and advancements in protein degradation from experts in the field.